Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03589716 · ClinicalTrials.gov registry record · NA
Evaluating the Accuracy of an Integrated Vital Sign Measurement Platform
A NA study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- NA
- Development phase
- 265
- Enrollment target
NCT03589716: Completed NA study, sponsored by Massachusetts General Hospital.
NCT03589716 is a NA study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 265 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (81% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03589716, a NA study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 265 participants
- Enrollment target
Study Summary
Partners Connected Health will conduct a clinical validation study to evaluate the accuracy of measurement for each vital sign with the Vital Moto Mod platform, compared to appropriate reference devices used in the hospital setting. The study will recruit volunteers from the Partners Healthcare network of clinics and hospitals and the general public.
Primary Outcome
Vital signs measurements for each participant would be compared using the Vital Moto Mod and reference devices for blood pressure, heart rate, respiratory rate, oxygen saturation and temperature
Interventions
- OTHER Vital Moto Mod
- OTHER Welch Allyn Connex Spot Vital Signs Monitor
- OTHER Capnostream 20 Portable Bedside Capnograph
- OTHER Welch Allyn 767 Mobile Aneroid Sphygmomanometerand 3M Littmann Master Classic II Teaching Stethoscope
- OTHER Scifit 1000R cycle ergometer
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 265 participants |
| Start Date | 2018-07-23 |
| Est. Completion | 2019-12-30 |
| Phase | NA |
What the finished NCT03589716 record still lists
NCT03589716 is an interventional study that assigns participants to a tested intervention. The registered 265 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (81% lower).
The record links to 0 conditions, and to 5 interventions - of which Vital Moto Mod is the first listed.
NCT03589716 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03589716 about?
NCT03589716 is a clinical study titled "Evaluating the Accuracy of an Integrated Vital Sign Measurement Platform". Partners Connected Health will conduct a clinical validation study to evaluate the accuracy of measurement for each vital sign with the Vital Moto Mod platform, compared to appropriate reference devices used in the hospital setting. The study will recruit volunteers from the Partners Healthcare netw...
What is the current status of trial NCT03589716?
This trial is currently completed. It is a NA study. The enrollment target is 265 participants. The study started on 2018-07-23. Estimated completion is 2019-12-30.
What interventions are being tested in trial NCT03589716?
The interventions under investigation include: Vital Moto Mod (OTHER), Welch Allyn Connex Spot Vital Signs Monitor (OTHER), Capnostream 20 Portable Bedside Capnograph (OTHER), Welch Allyn 767 Mobile Aneroid Sphygmomanometerand 3M Littmann Master Classic II Teaching Stethoscope (OTHER), Scifit 1000R cycle ergometer (OTHER).
Who is sponsoring clinical trial NCT03589716?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03589716's enrollment target sits among peer trials
265 395th of 2000 higher than 1,606 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05443126 · 265 participants · Phase 1
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
- NCT05470491 · 265 participants · Phase 1
Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...
- NCT07301905 · 265 participants · NA
Culturally Targeted Health Communication and Receptivity to the Human Papillomavirus Vaccine Among Parents in Flint, MI
- NCT07470853 · 265 participants · Phase 1
A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI